- Stocks
- Pharma & Healthcare
- Jubilant Pharmova
Jubilant Pharmova share price
NSE: JUBLPHARMAPharma & HealthcareDrug Manufacturers - Specialty & Generic
Jubilant Pharmova at a glance
Jubilant Pharmova (NSE: JUBLPHARMA) closed at ₹930.80 on 22 Oct 2026, down 0.02% on the day. With a market capitalisation of ₹14,848 Cr, it ranks 427th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 37.1× trailing earnings, against a return on equity of 13.4% in FY25. Over the past year the share price has fallen 13.4%. Its 52-week range is ₹786.05 (9 Mar 2026) to ₹1,183.00 (4 Nov 2025); the last close is 21.3% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹2,272 Cr (+18.6% year on year) and net profit ₹119 Cr (−21.2%), on a consolidated basis. Promoters held 47.68% of the company as of 30 Jun 2026; 6.58% of promoter shares were pledged.
Key numbers
- Market cap
- ₹14,848 CrRank 427 on NSE
- P/E (trailing)
- 37.1×
- Price to book
- 2.25×FY25
- EPS (TTM)
- ₹25.15to Q4 FY26
- ROE
- 13.4%FY25
- ROCE
- 8.1%FY25
- Debt to equity
- 0.39FY25
- Net profit margin
- 11.6%FY25
- Book value / share
- ₹395.88FY25
- Dividend payout
- 9.5%FY25
- 52-week high
- ₹1,183.004 Nov 2025
- 52-week low
- ₹786.059 Mar 2026
- 1-year return
- −13.4%
- RSI (14-day)
- 39.9
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.02% | −0.2% | −11.2% | −6.6% | −13.4% |
Jubilant Pharmova quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹1,720 Cr | ₹1,752 Cr | ₹1,814 Cr | ₹1,916 Cr | ₹1,879 Cr | ₹1,958 Cr | ₹2,116 Cr | ₹2,272 Cr |
| Revenue YoY | +9.8% | +5.1% | +8.9% | +9.7% | +9.2% | +11.7% | +16.7% | +18.6% |
| Net profit | ₹482 Cr | ₹103 Cr | ₹101 Cr | ₹151 Cr | ₹103 Cr | ₹120 Cr | ₹56 Cr | ₹119 Cr |
| Net profit YoY | +6,410.8% | +93.2% | +89.5% | — | −78.7% | +17.0% | −44.7% | −21.2% |
| Net margin | 28.0% | 5.9% | 5.6% | 7.9% | 5.5% | 6.1% | 2.6% | 5.3% |
| EPS | ₹30.44 | ₹6.47 | ₹6.37 | ₹9.71 | ₹6.49 | ₹7.59 | ₹3.52 | ₹7.55 |
Jubilant Pharmova financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹5,976 Cr | ₹6,099 Cr | ₹6,130 Cr | ₹6,282 Cr | ₹6,703 Cr | ₹7,235 Cr |
| Operating profit | ₹1,046 Cr | ₹881 Cr | ₹640 Cr | ₹72 Cr | ₹315 Cr | ₹622 Cr |
| Net profit | ₹898 Cr | ₹824 Cr | ₹423 Cr | −₹77 Cr | ₹49 Cr | ₹837 Cr |
| EPS (₹) | ₹56.00 | ₹52.00 | ₹26.00 | −₹4.00 | ₹5.00 | ₹53.00 |
| Cash from operations | ₹1,543 Cr | ₹1,784 Cr | ₹838 Cr | ₹661 Cr | ₹971 Cr | ₹1,072 Cr |
| Total debt | ₹3,740 Cr | ₹2,564 Cr | ₹2,464 Cr | ₹3,110 Cr | ₹3,167 Cr | ₹2,150 Cr |
| Shareholders' equity | ₹5,604 Cr | ₹4,741 Cr | ₹5,319 Cr | ₹5,399 Cr | ₹5,434 Cr | ₹6,255 Cr |
Jubilant Pharmova shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.68% | 47.68% | 47.68% | 47.68% | 47.68% | 47.68% |
| Foreign institutions | 17.22% | 17.40% | 16.57% | 15.96% | 15.90% | 15.87% |
| Domestic institutions | 7.05% | 9.53% | 10.52% | 11.22% | 11.62% | 12.40% |
| Non-institutions | 24.50% | 24.84% | 24.60% | 24.57% | 24.24% | 23.50% |
| Promoter shares pledged | — | — | 5.40% | 5.40% | 5.40% | 6.58% |
Jubilant Pharmova vs peers
The listed Pharma & Healthcare companies nearest to Jubilant Pharmova by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ERISEris Lifesciences | ₹1,143.60 | +0.76% | −27.9% | ₹15,537 Cr | 25.3 | 15.9% |
| APLLTDAlembic Pharmaceuticals | ₹785.00 | −0.41% | −14.0% | ₹15,357 Cr | 22.9 | 11.2% |
| ASTRAZENAstraZeneca Pharma India | ₹6,056.00 | −0.38% | −33.5% | ₹15,252 Cr | 80.9 | 15.0% |
| SYNGENESyngene International | ₹370.75 | −1.12% | −40.8% | ₹15,037 Cr | 47 | 6.5% |
| AGARWALEYEDr. Agarwal's Health Care | ₹459.10 | −1.51% | −10.7% | ₹14,852 Cr | 100 | 6.6% |
| JUBLPHARMAJubilant Pharmova | ₹930.80 | −0.02% | −13.4% | ₹14,848 Cr | 37.1 | 13.4% |
| POLYMEDPoly Medicure | ₹1,479.10 | +1.31% | −20.5% | ₹14,686 Cr | 46.7 | 10.4% |
Ask anything about Jubilant Pharmova
Pivot answers on the live chart with evidence you can check, and tests strategies against JUBLPHARMA's own history. Try: “Why has JUBLPHARMA moved over the last three months?” · “Backtest a 50-day moving-average crossover on JUBLPHARMA over five years” · “Compare JUBLPHARMA with ERIS on margins and valuation”
Frequently asked questions about Jubilant Pharmova
What is the share price of Jubilant Pharmova today?
Jubilant Pharmova (NSE: JUBLPHARMA) last closed at ₹930.80 on 22 Oct 2026. Its 52-week high is ₹1,183.00 and its 52-week low is ₹786.05.
What is the market cap of Jubilant Pharmova?
Jubilant Pharmova's market capitalisation is ₹14,848 Cr (₹14,848 Cr) at the 22 Oct 2026 close, ranking 427th among the NSE companies Pivot tracks.
What is the P/E ratio of Jubilant Pharmova?
Jubilant Pharmova trades at a trailing P/E of 37.1. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 47.
What is the ROE and ROCE of Jubilant Pharmova?
Return on equity was 13.4% in FY25 and return on capital employed was 8.1% in FY25 (consolidated figures).
Is Jubilant Pharmova a debt-free company?
No. Jubilant Pharmova's debt-to-equity ratio was 0.39 in FY25, with total debt of ₹2,150 Cr.
What were Jubilant Pharmova's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Jubilant Pharmova reported revenue of ₹2,272 Cr, +18.6% year on year, and net profit of ₹119 Cr, −21.2% year on year.
How has Jubilant Pharmova stock performed over the last year?
Jubilant Pharmova's share price has fallen 13.4% over the past year, −6.6% over three months and −11.2% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Jubilant Pharmova?
As of 30 Jun 2026: promoters 47.68%, foreign institutions 15.87%, domestic institutions 12.40%, non-institutions 23.50%. 6.58% of promoter shares were pledged.
Who are Jubilant Pharmova's competitors?
The listed Pharma & Healthcare companies closest to Jubilant Pharmova by market cap are Eris Lifesciences, Alembic Pharmaceuticals, AstraZeneca Pharma India, Syngene International, Dr. Agarwal's Health Care and Poly Medicure.
Is Jubilant Pharmova a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Jubilant Pharmova's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on JUBLPHARMA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with J · all NSE stocks · this page as text